January 12

ACNP Task Force Ties to Pharma

Joseph John Mann, M.D. — Task Force Co-Chair

The Paul Janssen Professor of Translational Neuroscience in Psychiatry and Radiology, Columbia University College of Physicians and Surgeons; Chief, Department of Neuroscience, New York State Psychiatric Institute; ACNP

Industry Affiliations:
•    Consultant and expert wtiness: GlaxoSmithKline, Pfizer, 2000, 2001 (lamotrigine; Zoloft)
•    Grants/Research Support: PET ligand development grant from Pfizer (2003), Beta-amyloid imaging grant from GlaxoSmithKline (2005)
•    Participated in GlaxoSmithKline Advisory group meeting on lamotrigine (2002);
•    Received three years of funding from Janssen Pharmaceutica for research involving all suicide victims in a region of Hungary  (http://www.hu.afsp.org/english/fr_hun_eng.htm); accessed 01/19/03);
•    Received funding from Eli Lilly for a study on the safety and biological mechanisms of action of norepinephrine and serotonin reuptake inhibitor antidepressants (1990).  (http://www.healyprozac.com/Trials/Tobin/Transcripts/5-31%20Suhaney-Mann.txt,  p.1622; accessed 01/19/04)   http://www.cspinet.org/cgi-bin/integrity.cgi

Graham Emslie, MD– Task Force Co-Chair

Chief, Division of Child and Adolescent Psychiatry and Professor of Psychiatry,
The University of Texas Southwestern Medical Center at Dallas; ACNP
Industry Affiliations:
•    Consultant/Speaker’s Bureau: Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, GlaxoSmithKline, McNeil, Otsuka, Pfizer, Inc. Wyeth-Ayerst
•    Grants/Research Support: Eli Lilly, Novartis, Organon
•    Serves on the Corporate Contributions and Research Committee for the American Academy of Child and Adolescent Psychiatry.
•    Leading participant in a consensus panel for child and adolescent bipolar disorder funded by:  Abbott, Brystol-Myers Squibb, GlaxoSmithKline, INC Research, Janssen, Johnson & Johnson, Eli Lilly, Novartis, Pfizer, and Solvay. Participants did not disclose compensation or affiliations. http://www.liebertpub.com/cap/jcappaper1.pdf
•    Served on Texas Children’s Medication  “Expert Consensus Panel”
•    Principle investigator fluoxetine (Prozac) pediatric trials resulting in FDA approval for use in children; Co-Author of dubious Paroxetine (Paxil) Study 329 Report: “Effacy of paroxetine in the treatment of adolescent major depression” (JAMA 2003; 290:1033-41). The report failed to disclose it was based on selected data. See sponsor (GSK) memo at: https://ahrp.org/risks/SSRI0204/GSKpaxil/index.php   (http://www3.utsouthwestern.edu/psychiatry/facbios/emslie.htm; http://www.cspinet.org/cgi-bin/integrity.cgi

Ross J Baldessarini, MD

Professor of Psychiatry and Neuroscience, Harvard Medical School
Director, Laboratories for Psychiatric Research, Mailman Research Center
Director, Bipolar & Psychiatric Disorders/Director, Psychopharmacology, McLean Hospital; ACNP
Industry Affiliations:
•    Consultant/Research Collaborator: Auritec Laboratories, Eli Lilly Laboratories, IFI SpA, Janssen Pharmaceuticals, JDS Corporation, NeuroHealing Pharmaceuticals, also Auritec, Biostream, Protarga, and Vertex, Protarga and Solvay. http://www.medscape.com/viewprogram/353_authors
•    Grants/Research Support: Eli Lilly Laboratories (former grant recipient), Janssen, also Biostream See:http://www.psychiatrist.com/achi/6409.pdf

William Beardslee, MD

Psychiatrist-in-Chief and Chair, Children’s Hospital Department of Psychiatry; Professor of Child Psychiatry, Harvard Medical School  No Industry Affiliations

Jan Fawcett, MD

Professor of Psychiatry, University of New Mexico; ACNP
Industry Affiliations:
•    Consultant: Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, Forest Laboratories, Janssen Pharmaceutica, GlaxoSmithKline, Merck & Co. Inc., Pfizer, Inc., Pharmacia & Upjohn, Wyeth-Ayerst Laboratories
•    Speaker’s Bureau: Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer/Roerig, Pharmacia, GlaxoSmithKline, Solvay Pharmaceuticals, Inc., Wyeth-Ayerst Laboratories
•    Grants/Research Support: National Institute of Mental Health, Abbott Laboratories, Astra Zeneca Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly and Company, Organon, Pfizer, Inc., Wyeth-Ayerst Laboratories  http://www.cspinet.org/cgi-bin/integrity.cgi

Fred Goodwin, MD

Research Professor of Psychiatry and Director, Psychopharmacology Research Center, George Washington University; Former Director of the National Institute of Mental Health; ACNP
Industry Affiliations:
•    Consultant: Glaxo, Lilly, Pfizer, Bristol Myers Squibb, Solvay. Elan, Novartis
•    Speakers Bureau: Bristol Myers Squibb, Solvay, Glaxo, Pfizer, Janssen, Lilly, AstraZeneca, Grants/Research Support: Abbott Laboratories, Glaxo, Solvay, Janssen, Pfizer, Lilly, Forest, Sanofi.
•    Participated in a consensus panel for child and adolescent bipolar disorder funded by: Abbott, Brystol-Myers Squibb, GlaxoSmithKline, INC Research, Janssen, Johnson & Johnson, Eli Lilly, Novartis, Pfizer, and Solvay.
Participants did not disclose compensation or affiliations. http://www.liebertpub.com/cap/jcappaper1.pdf

Andrew C Leon, PhD

Professor of Biostatistics in Psychiatry and Professor of Public Health,
Weill Medical College of Cornell University.
Industry Affiliations:
•    Consultant: Cyberonics, Inc., Cortex Pharmaceuticals, Pfizer.
•    Wrote a manuscript and presentation for Forest Laboratories titled, "Are Two Antidepressant Mechanisms Better than One? Issues in Clinical Trial Design and Analysis."   On file with CSPI)  http://www.cspinet.org/cgi-bin/integrity.cgi

Herb Meltzer, MD

Professor of Psychiatry & Pharmacology, Director Division of Psychopharmacology
President, Collegium Internationale Neuropsychopharmacologicum (CINP),
Vanderbilt University Medical Center; ACNP
Industry Affiliations:
•    Consultant, Speaker’s Bureau, Honorarium,
•    Grant/Research Support: Eli Lilly, Pfizer, GlaxoSmithKline, Janssen, AstraZeneca

Neal Ryan, MD

Professor of Psychiatry, Western Psychiatric Institute & Clinic, University of Pittsburgh; ACNP
Industry Affiliations:
•    Consultant: GlaxoSmithKline (designed study and a performance site for the GSK study of paroxetine in adolescents and was second author on the resulting publication* as well as a co-author on related letters to the editor including one letter related to suicidality assessment in that study)
•    Consultant: GlaxoSmithKline (examination of their data related to suicidality in their aggregate paroxetine data.)
•    Consultant (design of studies of antidepressants in youth): Pfizer, GSK, and Wyeth
•    Primary Investigator: Wyeth (Pittsburgh performance site for the study of Venlafaxine (Effexor) and children.)
•    Served on Texas Children’s Medication  “Expert Consensus Panel”
•    *Co-Author of dubious Study 329 Report: See Emslie note (above).
    On file with CSPI)  http://www.cspinet.org/cgi-bin/integrity.cgi

David Shaffer, MD

Professor of Child Psychiatry, and Professor of Psychiatry and Pediatrics,
Columbia University College of Physicians and Surgeons; Director, Division of Child Psychiatry, New York State Psychiatric Institute
Industry Affiliations:
•    Consultant: Hoffman la Roche, Wyeth (expert trial witness)
•    Consultant: GlaxoSmithKline (on the matter of paroxetine (Paxil) and adolescent suicide)
•    Participated in a consensus panel for child and adolescent bipolar disorder funded by: Abbott, Brystol-Myers Squibb, GlaxoSmithKline, INC Research, Janssen, Johnson & Johnson, Eli Lilly, Novartis, Pfizer, and Solvay.
    Participants did not disclose compensation or affiliations. http://www.liebertpub.com/cap/jcappaper1.pdf
According to the New York Times, "Shaffer…sent a letter at Pfizer’s request to the British drug agency, [saying] he had concluded that there was insufficient data to restrict the use of in adolescents." (NY Times, 12/11/03, A1) http://query.nytimes.com/gst/fullpage.html?res=9C02E4DD173CF932A25751C1A9659C8B63&sec=health&pagewanted=all

Karen Wagner, MD, PhD

Director, Division of Child and Adolescent Psychiatry; Professor and Vice Chair, Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, Galveston; ACNP
Industry Affiliations:
•    Consultant: Abbott Laboratories, Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest Laboratories, Glaxo-Smith Kline, Janssen, Novartis, Otskua, Pfizer, UCB Pharma, Wyeth-Ayerst
•    Speaker’s Bureau: Abbott Laboratories, Eli Lilly and Co., Forest Laboratories, Glaxo-Smith Kline, Janssen, Novartis, Pfizer Inc.
•    Advisory Board: Abbott Laboratories, Eli Lilly and Co., Forest Laboratories, Glaxo-Smith Kline, Janssen, Novartis, Otsuka, Pfizer, UCB Pharma, Wyeth-Ayerst
•    Research Support: Abbott, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Organon, Pfizer, Wyeth-Ayerst, National Institute of Mental Health
•    Served on Texas Children’s Medication  “Expert Consensus Panel”
•    Co-Author of dubious Study 329 Report: Effacy of paroxetine in the treatment of adolescent major depression (See note at Emslie above)        http://www.cspinet.org/cgi-bin/integrity.cgi

~~~~~~~~

ACNP ACKNOWLEDGMENTS

The ACNP Task Force on SSRIs and Suicide received no fees and the cost of the report was supported solely by the ACNP.
The ACNP also receives a substantial share of its revenue from pharmaceutical industry grants.  
•    The American College of Neuropsychopharmacology gratefully acknowledges the following companies in support of the 44th ACNP Annual Meeting (December 2005):
•    Bristol-Myers Squibb Company; Cyberonics, Inc.; Eli Lilly and Company; Forest Laboratories; GlaxoSmithKline; Janssen Pharmaceutica Products, L.P. Otsuka Maryland Research; Pfizer Pharmaceuticals; Wyeth Pharmaceuticals http://www.acnp.org/pdffiles/AM2005Program.pdf

*Compiled by Allen Jones, AHRP Board member.


Subscribe To Our Newsletter!

Sign up and be the first to find out the latest news and articles about what's going on in the medical field.


You may also like

September 29, 2022

“Here we will have to really think medical-legal. Why medical-legal? Because [despite] quite a few adverse events

Read More
Israeli Government Officials Concealed Evidence Documenting Irreparable Harm Following Covid-19 Jabs

September 20, 2022

Stop the World Health Organization Treaty that would dictate global public health policy — in other words,

Read More
Vera Sharav Statement Against Efforts by the World Health Organization to Dictate Global Health Policy